Serodus is a private Scandinavian drug development company with a pipeline focusing on novel, immuno-modulators stopping progression of diabetic kidney desease. Lead candidate SER150 targets Diabetic Kidney Disease, representing an attractive market and significant recognized unmet medical need. SER150 showed positive phase 2a development results. A confirmatory clinical study is expected to start during 2021-H1. All currently available treatments for T2D are initially effective in reducing blood glucose and reduce complication rates, but they lack the ability to stop the systemic inflammation driving the pathophysiological processes of diabetes and its complications. Our candidates target the fundamental underlying systemic inflammation causing diabetes and its comorbidities.